Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: November 16, 2023
Reporting Period: Events occurring on November 16 and November 17, 2023.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, or margin data. Key financial figures disclosed relate to listing compliance:
- Stockholders' Equity: $1,236,558 (as reported in the Form 10-Q for the period ended September 30, 2023).
- Minimum Equity Requirement: $2,500,000 (Nasdaq Listing Rule 5550(b)(1)).
- Stock Price: Below $1.00 per share for the last 30 consecutive business days prior to November 16, 2023.
- Shares Outstanding: 2,330,399 (as of September 28, 2023 record date).
- Shares Voted: 1,123,443 (approximately 48.21% of outstanding shares).
Material Changes and Events
The Company received two notices of noncompliance from Nasdaq on November 16, 2023:
- Stockholders' Equity Deficiency: The Company failed to meet the minimum $2.5 million stockholders' equity requirement. Nasdaq granted a deadline of January 2, 2024, to submit a compliance plan. If accepted, the Company may receive up to 180 days to regain compliance.
- Minimum Bid Price Deficiency: The Company failed to maintain a minimum bid price of $1.00 per share. The Company has a 180-day compliance period until May 14, 2024, to regain compliance. Failure to do so may result in delisting unless a reverse stock split is effected or an additional 180-day extension is granted.
On November 17, 2023, the Company held a Special Meeting of stockholders where three proposals were approved:
- Proposal 1: Approval of the issuance of up to 15,921,888 shares (or 16,727,272 with full overallotment) upon exercise of warrants issued in October 2023.
- Proposal 2: Ratification of UHY LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2024.
- Proposal 3: Authorization to adjourn the Special Meeting to solicit additional proxies if necessary for Proposal 1.
Outlook, Risks, and Management Commentary
Management Commentary: The Company believes it is currently in compliance with the minimum stockholders' equity requirement as of the date of the report and plans to submit a compliance plan to Nasdaq. However, management states there can be no assurance that the plan will be accepted or that compliance will be maintained.
Risks and Contingencies:
- Delisting Risk: If the compliance plan is rejected, or if the Company fails to regain compliance within the allotted timeframes (including the bid price requirement), Nasdaq may initiate delisting proceedings.
- Reverse Stock Split: To qualify for an additional 180-day extension for the bid price deficiency, the Company may need to effect a reverse stock split, which must be completed no later than ten business days prior to the expiration of the compliance period.
- Appeal Rights: The Company retains the right to appeal any delisting determination or rejection of a compliance plan to a Nasdaq Hearings Panel.
Investor Verification Checklist
- Verify the Company's submission of a compliance plan to Nasdaq by the January 2, 2024 deadline.
- Monitor the daily closing bid price to determine if it reaches $1.00 for 10 consecutive business days before May 14, 2024.
- Review the definitive proxy statement filed on October 20, 2023, for details on the warrant issuance approved in Proposal 1.
- Check for any subsequent announcements regarding the acceptance of the equity compliance plan or the implementation of a reverse stock split.
- Confirm the Company's status regarding the minimum bid price requirement in future 8-K filings or Nasdaq announcements.